Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
Recruiting
Observational Study
Adult Congenital Heart Disease
Congenital Heart Disease
Systemic Right Ventricle
Transposition of the Great Arteries
Congenitally Corrected Transposition of the Great Arteries
Fontan
Single Ventricle
Tetralogy of Fallot (TOF)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 400 (estimated)
- Sponsor
- Leiden University Medical Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Congenital heart defect.
* Age ≥ 18 years.
* Initiated on treatment with an SGLT2i.
Exclusion Criteria:
\- No consent for data collection.
Contacts